A Novel Unsupervised Method to Identify Genes Important in the Anti-viral Response: Application to Interferon/Ribavirin in Hepatitis C Patients

Leonid I. Brodsky, Abdus S. Wahed, Jia Li et al. · 2007

Read A Novel Unsupervised Method to Identify Genes Important in the Anti-viral Response: Application to Interferon/Ribavirin in Hepatitis C Patients by Leonid I. Brodsky, Abdus S. Wahed, Jia Li et al. (2007) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0000584.txt.

Introduction

Leonid I. Brodsky and colleagues designed a method to find genes that matter in antiviral defense without prior guesses, in a 2007 PLOS ONE paper. Their novel unsupervised method identifies genes important in the anti-viral response, and they applied it to patients receiving interferon and ribavirin for hepatitis C.

Unsupervised means the method finds its own patterns in the data rather than testing a preset list. In hepatitis C, only some patients respond to interferon therapy, and the gene signature of response was unclear. A method that surfaces the important genes could predict who benefits and reveal new drug targets.

Catalog record

CREATORLeonid I. Brodsky, Abdus S. Wahed, Jia Li et al.
YEAR2007
COLLECTIONPAPERS
FORMATTXT
FILE SIZE45 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0000584

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

A Novel Unsupervised Method to Identify Genes Important in the Anti-viral Response: Application to Interferon/Ribavirin in Hepatitis C Patients Authors: Leonid I. Brodsky, Abdus S. Wahed, Jia Li, John E. Tavis, Takuma Tsukahara, Milton W. Taylor Published: 2007, PLOS ONE DOI: 10.1371/journal.pone.0000584 ABSTRACT Treating hepatitis C with interferon/ribavirin results in a varied response in terms of decrease in viral titer and ultimate outcome. Marked responders have a sharp decline in viral titer within a few days of treatment initiation, whereas in other patients there is no effect on the virus (poor responders). Previous studies have shown that combination therapy modifies expression of hundreds of genes in vitro and in vivo. However, identifying which, if any, of these genes have a role in viral clearance remains challenging. The goal of this paper is to link viral levels with gene expression and thereby identify genes that may be responsible for early decrease in viral titer. Microarrays were performed on RNA isolated from PBMC of patients undergoing interferon/ribavirin therapy. Samples were collected at pre-treatment (day 0), and 1, 2, 7, 14 and 28 days after initiating treatment. A novel method was applied to identify genes that are linked to a decrease in viral titer during interferon/ribavirin treatment. The method uses the relationship between inter-patient gene expression based proximities and inter-patient viral titer based proximities to define the association between microarray gene expression measurements of each gene and viral-titer measurements. We detected 36 unique genes whose expressions provide a clustering of patients that resembles viral titer based clustering of patients. These genes include IRF7, MX1, OASL and OAS2, viperin and many ISG's of unknown function. The genes identified by this method appear to play a major role in the reduction of hepatitis C virus during the early phase of treatment. The method has broad utility and can be used to analyze response to any group of factors influencing biological outcome such as antiviral drugs or anti-cancer agents where microarray data are available. INTRODUCTION Treating with peginterferon/ribavirin combination therapy patients who have chronic hepatitis C virus (HCV) infection results in a varied response in terms of outcome and decrease in viral titer [1] – [4] . For patients who respond well there is a sharp decrease in viral titer within 24–48 hours after treatment initiation whereas in other patients there is little or no effect on the viral titer and only temporary, or no, clearance of the virus over a long period [5] , [6] . Previous in vitro studies have shown that combination interferon treatment induces or decreases expression of hundreds of genes [7] – [10] . One of the major problems, however, is to identify which of these genes are linked to viral clearance in vivo. In this paper we report a novel mathematical method to explore the association between decrease in viral titer and changes in gene expression in hepatitis C patients following combination treatment with pegylated interferon and ribavirin. The viral clearance time course profile will not necessarily directly correlate with the gene expression time course profile even if the gene is an active participant of the interferon treatment response because the decrease of the viral levels depends on the interplay of many genes and gene products. Therefore, an indirect approach was used in which the relationship between gene expression across days and viral decrease was examined using inter-patient distances (proximity) according to both characteristics. Using this approach we selected thirty seven gene probes that were linked with the anti-HCV response during the first 28 days of treatment. A visual demonstration of the association of detected genes with the viral decrease is demonstrated by a comparison of patient clusterings. Indeed, the inter-patient proximities according to the pattern of decrease in virus titer provide an unsupervised clustering of patients based on changes in viral levels. Similarly, the inter-patient proximities according to expressions of the specified genes across time provide another unsupervised clustering of patients. A visual inspection of viral-titer based and selected genes expression based clusterings of patients indicates their close relationship. Since the unsupervised clustering of patients according to the pattern of viral clearance is in good correspondence with an a priori biological categorization of patients into marked, slow and poor response at day 28 [11] ,the selected subset of genes can be considered as genes that are involved specifically in treatment response. Such genes products may have anti-viral activity or be related to the immune response against virus-infected cells. MATERIALS AND METHODS The Virahep-C study included a cohort of 401 participants who provided written consent at 8 U.S. clinical centers between September 9, 2002 and January 7, 2004. Per protocol, all participants were treated for up to 48 weeks with pegylated interferon alfa-2a (PEGASYS, Roche Inc. Nutley, NJ) at 180 mcg weekly by self-administered subcutaneous injection and ribavirin (COPEGUS, Roche, Inc. Nutley N.J.) by mouth at 1000 mg/day for those who weighed less than 75 kg or 1200 mg/day for those who weighed at least 75 kg. Treatment was discontinued at week 24 in participants who had a detectable serum HCV RNA virus in duplicate qualitative assays using the Roche Cobas Amplicor HCV Test, v2.0 (sensitivity 50 IU/ml). The primary endpoint of the study was the sustained virologic response, defined as an undetectable serum HCV RNA at week 72 (at least 24 weeks after completion of treatment). The clinical trial was #-NCT00038974. Fifty two patients for whom gene expression and viral level data were available at all time points were selected for this analysis. Based on the log-decline in serum HCV RNA on day 28 of treatment relative to day 0, as measured by the quantitative Roche Cobas Monitor HCV Test, v2.0 (sensitivity 600 IU/ml) these patients were divided into three groups [11] Patients were identified as poor responders if they had less than a 1.4 log 10 IU/ml decrease in serum HCV RNA between day 0 and day 28, as marked responders if they experienced more than a 3.5 log 10 IU/ml decrease or if their viral titers dropped to undetectable by day 28, and as intermediate responders if the log 10 drop in HCV RNA was between 1.4 and 3.5 IU/ml. For the purpose of unsupervised clustering of viral titers, patients with undetected viral levels by the quantitative assay were assigned a viral level of 599 IU/ml and those whose viral levels were undetected by the qualitative assay were assigned a viral level of 49 IU/ml This study met all necessary approvals of Institutional Review Boards of each institution participating in the Virahep-C consortium (Beth Isreal Deaconess Medical Center, New York Presbyterian Medical Center, Rush University, University of California at San Francisco, University of Maryland, University of Miami, University of Michigan, and University of North Carolina). CELL PREPARATION AND RNA EXTRACTION Peripheral Blood Mononuclear Cells (PBMC) were collected in sodium heparin-CPT tubes at day 0, 1, 2, 7, 14 and 28. Samples were shipped overnight from each clinical center to a central repository by express courier at 4°C. Whole blood was diluted with an equal volume (8 ml) of phosphate buffered saline, carefully layered over a 10 ml Ficoll-Hypaque gradient (Amersham/Pharmacia) and centrifuged at 800 rpm for 20 minutes at room temperature. The buffy coat layer was transferred

Read the complete text